Animal-Sourced Insulin Discontinuation in Canada: What the May 2026 Hypurin Expiry and Special Access Pathway Mean for Affected Patients

What This Means for You

If you or someone in your family depends on Hypurin (porcine) insulin, the next four to twelve weeks will determine your transition plan. This is one of the rare drug-shortage situations in Canada where the affected population is small — between 60 and 100 patients nationwide, according to Health Canada — but the clinical stakes for each individual are unusually high.

Animal-sourced insulin has not been available in the United States or Australia since the early 2000s. Canada was one of the last developed countries where Hypurin was still imported, largely because a small group of long-term patients reported significantly better blood-sugar control or fewer hypoglycemic episodes on porcine insulin than on the synthetic analogue insulins that are now standard. Based on our analysis of the Health Canada notices, statements from the Canadian Society of Endocrinology and Metabolism (CSEM), and reporting from The Globe and Mail, here is the practical playbook.

If You Currently Use Hypurin (Porcine) Insulin:

Immediate action this week:

Do not stop or skip insulin doses under any circumstances. This is the single most important rule. CSEM has explicitly warned that abrupt discontinuation of insulin is life-threatening for Type 1 diabetes.
Book an appointment with your endocrinologist or diabetes specialist within the next 7 to 14 days. If you don't have one, ask your family physician for an urgent referral. Tell the booking desk this is a "drug discontinuation transition consult" — that phrasing typically secures faster appointments.
Inventory your remaining Hypurin supply. Count vials, check expiry dates on each (the remaining imported supply expires May 2026), and write down how many days of coverage you have at your current dose.
Do not stockpile. CSEM has specifically advised both patients and prescribers against ordering large quantities of the remaining supply, both because the stock is finite and because hoarding by some patients leaves others without enough to transition safely.

What to prepare for your specialist visit:

A complete log of your blood glucose readings for the previous two to four weeks
Your current insulin regimen (units of basal and bolus, timing, correction factors)
A note of any past episodes of severe hypoglycemia, hospital admissions related to diabetes, or known reactions to specific insulin analogues
Questions about Health Canada's Special Access Program (SAP) — your physician will likely need to apply on your behalf if you wish to continue on porcine insulin

Understanding your transition options:

According to CSEM guidance, most patients who transition from animal-sourced to synthetic human insulin or to analogue insulin can do so safely. The literature reviewed by CSEM and international diabetes societies has not documented adverse outcomes from properly supervised transitions. However, your transition plan should be patient-specific, not a one-size-fits-all switch:

Direct human-insulin substitution. Some patients transition from porcine to synthetic regular and NPH human insulins with relatively minor dose adjustments. Expect closer monitoring during the first two to four weeks.
Switch to analogue insulins. Rapid-acting analogues (lispro, aspart, glulisine) and long-acting analogues (glargine, detemir, degludec) may offer more flexible dosing, but the timing and effect profile differs from porcine insulin and your specialist will need to recalibrate.
Adjunctive therapy. Some patients may benefit from adding a GLP-1 receptor agonist or other adjunctive agent. CSEM has flagged this as worth discussing for selected patients.

Special Access Program (SAP) — the new pathway:

In late March 2026, Wockhardt reversed its earlier position and agreed to make Hypurin available to Canadian patients through Health Canada's Special Access Program. SAP is the federal mechanism that allows physicians to request unlicensed or discontinued drugs for patients with serious or life-threatening conditions when no acceptable alternative is available.

What you and your physician need to know about SAP:

Your physician must submit an SAP request to Health Canada on your behalf
The request must be re-submitted every three months — there is no permanent authorization
Approval is at Health Canada's discretion and is patient-specific
According to reporting by The Globe and Mail, "the paperwork can be onerous," and physicians have flagged the administrative burden as a real barrier
Drug supply through SAP is not guaranteed — it depends on Wockhardt continuing to make product available and on Health Canada's case-by-case approvals

Cost considerations:

If you have a private drug plan, contact your insurer immediately to confirm whether porcine insulin obtained through SAP will be covered
Provincial drug plans may not automatically cover SAP-sourced medication — confirm with your provincial program
Wockhardt previously sought a Health Canada fee waiver (the application fee for the new cartridge format ranged from $44,269 to $320,000, according to reporting). Health Canada declined that waiver, which is part of why the discontinuation happened in the first place. This commercial dispute is unresolved.

If You're the Parent or Caregiver of a Type 1 Diabetes Patient on Hypurin:

The vast majority of patients on porcine insulin are long-term users, but the population includes some pediatric and teenage patients. The Globe and Mail's reporting focused on a 16-year-old Ontario patient whose family expressed cautious optimism about the SAP pathway but anxiety about the three-month renewal cycle.

Your role as a caregiver:

Maintain a written record of every prescription, refill, lot number, and expiry date during the transition
Keep an emergency supply of glucagon (and a backup) — risk of severe hypoglycemia can rise temporarily during any insulin transition
Confirm school, work, or daycare medical plans are updated with the new insulin regimen
Connect with Diabetes Canada's patient-support line for transition guidance

If You're a Pharmacist or Family Physician:

You may be the first point of contact for patients realizing their long-term insulin is going away. CSEM's clinical guidance is unambiguous on two points: do not initiate new patients on Hypurin (no point starting a therapy you can't continue), and meet proactively with existing Hypurin patients to plan transitions before supplies run out.

Practical steps:

Identify Hypurin users in your patient panel using dispensing records
Reach out proactively — do not wait for the patient to flag a problem
Coordinate with the endocrinology team in your region; some provinces have set up specific transition clinics
Document SAP applications carefully — incomplete forms are the most common reason for delay

For All Canadians Following This Story:

This is a small population, but the policy issues are large. Decisions about which medications stay available in Canada are shaped by a combination of regulatory fees, manufacturer commercial choices, and Health Canada's willingness to invoke special-access mechanisms. The Hypurin discontinuation is being watched closely by patient-advocacy groups for other small-population medications — including certain animal-derived thyroid medications, niche cardiac drugs, and older formulations that have been displaced by newer analogues.

The News: What Happened

According to Health Canada's drug-shortage supply notice, Wockhardt UK — the only current global supplier of porcine insulin — informed Health Canada it would no longer supply animal-sourced insulin products for the Canadian market, with no additional inventory available after the existing supply is depleted.

As reported by The Globe and Mail, Hypurin Regular Pork Insulin became unavailable earlier in 2026, and the remaining supply of Hypurin NPH carries an expiry of April–May 2026. The Globe and Mail further reported that, on March 27, 2026, Wockhardt reversed its earlier position and agreed to participate in Health Canada's Special Access Program, opening a discretionary pathway for individual patients to continue receiving the medication.

According to the Canadian Society of Endocrinology and Metabolism, approximately 60 to 100 Canadians currently rely on animal-sourced insulin, and Health Canada is working with the importer to monitor the remaining supply and explore options to extend availability while transitions are arranged.

The Globe and Mail also reported that Health Canada declined Wockhardt's request to waive application fees ranging from $44,269 to $320,000 for a reformulated cartridge product, with Health Canada stating that the company did not qualify under criteria for small businesses or urgent public health needs.

Analysis: Why This Matters

Based on our analysis of how Canada has handled small-population drug-supply situations over the past decade, the Hypurin case sits at the intersection of three policy tensions that are unlikely to go away.

First, the regulatory-fee question. Health Canada charges manufacturers fees to recover the cost of reviewing new drug submissions. Those fees are designed for large commercial products, and they are an effective barrier to bringing very small-volume drugs to market. The Hypurin situation is now the most-cited example of this barrier.

Second, the Special Access Program is doing work it was not originally designed for. SAP was conceived as a short-term bridge for individual patients facing life-threatening conditions with no alternative. Using it as a long-term supply route for a stable, chronic-disease population — re-applied every three months — puts considerable administrative load on prescribers and creates ongoing uncertainty for patients.

Third, the international clinical context matters. Other developed countries have not had patients on animal-sourced insulin for two decades, and the published evidence does not show that switching to synthetic insulin causes harm at a population level. But population-level data does not always speak to the individual patient who reports consistent personal benefit from porcine insulin, and Canadian regulators have generally been more accommodating of these patient-specific accounts than their counterparts in the U.S. or Australia.

Historical Context:

Animal-sourced insulin saved millions of lives between its 1922 Canadian discovery and the introduction of recombinant human insulin in the 1980s. Most countries phased out animal insulin in the 1990s and early 2000s as synthetic and analogue insulins demonstrated comparable or superior outcomes at scale. Canada retained imported porcine insulin for the small group of patients who reported difficulty on synthetic forms.

What Happens Next:

Based on our reading of the public record, the most likely scenario in the next 6 to 12 months is that:

Existing patients will work through individualized transition plans with their endocrinology teams over the rest of 2026.
A subset of patients will continue on Hypurin via SAP for as long as Wockhardt remains willing to supply.
Health Canada and patient-advocacy groups will continue debating whether the regulatory-fee framework needs adjustment for orphan-population products.
The Hypurin case will likely be cited in any future review of Canada's drug-shortage prevention and special-access systems.

Your Action Plan

Immediate (This Week):

If you or a family member uses Hypurin, book an endocrinologist or diabetes-clinic appointment within 7 to 14 days
Inventory remaining Hypurin supply, including expiry dates
Confirm whether your private or provincial drug plan will cover SAP-sourced insulin
Do not order extra Hypurin — leave supply for others mid-transition

Short-term (This Month):

Work with your physician on a written transition plan
If choosing to remain on porcine insulin, ensure your physician submits an SAP application
Refresh your hypoglycemia emergency plan (glucagon kits, contact list)
Set up more frequent blood-glucose monitoring for the transition period

Long-term (This Year):

Build a quarterly check-in with your specialist for at least the next 12 months
If on SAP, mark every three-month renewal date in your calendar
Stay connected with Diabetes Canada and patient-advocacy networks for updates
Document any post-transition issues in writing — this evidence informs future policy reviews

Other Perspectives

Health Canada View:

According to Health Canada's official supply notice, the regulator is monitoring remaining inventory, exploring extension options, and emphasizing that human insulin and insulin analogues remain available and effective for the management of diabetes.

Clinical Specialist View:

According to guidance published by the Canadian Society of Endocrinology and Metabolism, the available evidence shows that most patients can be safely transitioned from animal-sourced to synthetic human or analogue insulins, though transitions should be patient-specific and closely monitored.

Patient-Advocacy View:

According to commentary cited by The Globe and Mail from longtime patient and health researcher Colleen Fuller, porcine insulin is an essential medicine for the patients who depend on it, and regulators should be facilitating — not obstructing — access for a small population whose alternative options are limited.

Manufacturer View:

According to reporting by The Globe and Mail, Wockhardt sought a waiver of Health Canada application fees in light of the small Canadian patient population. After that waiver was declined, the company indicated it would not bring the new cartridge format to Canada, but later agreed in March 2026 to make product available through the Special Access Program on a case-by-case basis.

Note: Including multiple perspectives doesn't imply all views are equally valid, but ensures readers can make informed judgments.

Corrections Policy

We strive for accuracy. If you find an error in this analysis, please email us at [email protected]. We will promptly investigate and correct any factual inaccuracies.

Updates:

No corrections to date (as of 2026-05-26)

Sources

Health Canada: "Animal-sourced insulin discontinuation: Notice" — canada.ca
The Globe and Mail: "Diabetes patients who rely on animal insulin may get access to discontinued medicine" — theglobeandmail.com (April 10, 2026)
The Globe and Mail: "Loss of animal insulin in Canada highlights how patients can be left behind" — theglobeandmail.com
Canadian Society of Endocrinology and Metabolism: "Hypurin Regular Pork Insulin" — endo-metab.ca
Canadian Pharmacists Association: "Hypurin (porcine insulin) discontinuation" briefing for health care professionals — pharmacists.ca
Health Canada: "Importation of UK-authorized Hypurin Porcine Neutral Insulin Injection" — recalls-rappels.canada.ca
Diabetes Canada: "Discontinuation of Beef Insulin" — diabetes.ca